For Your Patients: What to Know About Breast Cancer HER2 Status. Story by Shalmali Pal • 14h. B reast cancer is a complex disease with many types. ... Hormone Receptor (HR) and HER2 Status.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low ...

AP402 targets p95HER2, a truncated HER2 variant, and activates T-cells in the tumor microenvironment, potentially reducing systemic toxicity. The phase 1/2 trial evaluates AP402's safety, tolerability ...

OST-HER2 was determined to be safe and well tolerated in patients with HER2-expressing solid tumors, including at the dose currently being used in the Company’s ongoing Phase 2b clinical trial ...

Cohort 1 included 80 patients with HER2-positive disease, defined as IHC2+/3+ status. Cohort 2 included seven patients with IHC0/1+ status.

So, for instance, our patients who have progressive disease in the brain, are eligible for local therapy and have controlled extracranial disease, we still recommend continuing the current ...

Patients with RAS/BRAF-WT mCRC after central confirmation of HER2 positivity (immunohistochemistry 3+ or 2+ and in situ hybridization amplified [HER2/CEP17 ratio >2.0]) were assigned (1:1) to either ...

In the study, which is sponsored by AFT, median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with palbociclib in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus ...

Patients with actionable genomic alterations were previously treated with platinum ... About Hormone Receptor Positive, HER2 Negative Breast Cancer More than 500,000 breast cancer cases were ...